ABN 16 165 160 841 +61 (0) 3 9123 1140 | [email protected] Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 06 AUGUST 2026 ASX RELEASE BIOSHARES BIOTECH SUMMIT PRESENTATION – TARGETING PANCREATIC CANCER AND BEYOND Amplia Therapeutics Limited...
Bioshares Biotech Summit Presentation
Filed with ASX · · 29 pages · English
Release
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Amplia signs Collaboration and Supply Agreement with Lilly
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Scientific Paper Studies of narmafotinib - Pancreatic Cancer
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notice of Annual General Meeting/Proxy Form
Later from Amplia Therapeutics
- CEO Managing Director Presentation to Annual General Meeting
- Results of Annual General Meeting
- Notification regarding unquoted securities - ATX
- Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial
- Amplia Presents at E&P Healthcare Conference 2026
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics